Trial Profile
A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Sep 2011
Price :
$35
*
At a glance
- Drugs Vadimezan (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 04 Feb 2011 New trial record